athenahealth offers client base free CommonWell services

As part of its effort to advance patient-centered information exchange, today at HIMSS athenahealth announced it has made CommonWell services available to its entire client base of more than 62,000 healthcare providers nationwide.

Its cloud-based model allows athenahealth to enable instant access to CommonWell's interoperability services. In partnership with its clients, athenahealth will work to bring as many of the patients who are treated by its provider clients onto the CommonWell network.

"With 79 percent of physicians saying that the vast majority of patients they treat also receive care from caregivers outside their core network, it's critical for information to follow the patient," said Todd Rothenhaus, MD, chief medical officer and SVP of Network Knowledge at athenahealth, in a release. "Just as we partnered with our clients to succeed at Meaningful Use, achieving a 98 percent Stage 2 attestation rate when the industry is only at about 30 percent, we will work with our clients to achieve meaningful information exchange. We believe healthcare organizations that embrace patient-centered information exchange will be the most profitable in the future."




 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.